Visual perception and its impairment in schizophrenia.
Much work in the cognitive neuroscience of schizophrenia has focused on attention, memory, and executive functioning. To date, less work has focused on perceptual processing. However, perceptual functions are frequently disrupted in schizophrenia, and thus this domain has been included in the CNTRICS (Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia) project. In this article, we describe the basic science presentation and the breakout group discussion on the topic of perception from the first CNTRICS meeting, held in Bethesda, Maryland on February 26 and 27, 2007. The importance of perceptual dysfunction in schizophrenia, the nature of perceptual abnormalities in this disorder, and the critical need to develop perceptual tests appropriate for future clinical trials were discussed. Although deficits are also seen in auditory, olfactory, and somatosensory processing in schizophrenia, the first CNTRICS meeting focused on visual processing deficits. Key concepts of gain control and integration in visual perception were introduced. Definitions and examples of these concepts are provided in this article. Use of visual gain control and integration fit a number of the criteria suggested by the CNTRICS committee, provide fundamental constructs for understanding the visual system in schizophrenia, and are inclusive of both lower-level and higher-level perceptual deficits.
Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA. butler@nki.rfmh.org
Pamela D
PD
Butler
Steven M
SM
Silverstein
Steven C
SC
Dakin
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D035843:Biomedical Research; D001931:Brain Mapping; D003072:Cognition Disorders / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D003299:Cooperative Behavior; D015195:Drug Design; D006801:Humans; D009483:Neuropsychological Tests; D010468:Perceptual Disorders / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D014795:Visual Pathways / Q000187:drug effects / Q000503:physiopathology; D014796:Visual Perception / Q000187:drug effects* / Q000502:physiology*
D014150:Antipsychotic Agents